-
公开(公告)号：US12121569B2
公开(公告)日：2024-10-22
申请号：US17578119
申请日：2022-01-18
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Gaozhong Zhu , Kris Lowe , Zahra Shahrokh , James Christian , Richard Fahrner , Jing Pan , Teresa Leah Wright , Pericles Calias
IPC: A61K38/47 , A61K9/00 , A61K9/08 , A61K9/19 , A61K35/76 , A61K35/761 , A61K38/46 , A61K47/02 , A61K47/26 , C07K14/65 , C12N9/24 , C12N9/42
CPC classification number: A61K38/47 , A61K9/0019 , A61K9/0085 , A61K9/08 , A61K9/19 , A61K35/76 , A61K35/761 , A61K38/46 , A61K38/465 , A61K47/02 , A61K47/26 , C07K14/65 , C12N9/2402 , C12N9/2437 , C12Y301/06008 , C12Y301/06013 , C12Y302/01045 , C12Y302/01046 , C12Y302/0105 , C12Y310/01001
Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome.
-
公开(公告)号：US12110343B2
公开(公告)日：2024-10-08
申请号：US17684460
申请日：2022-03-02
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Andrew Nixon , Jon A. Kenniston , Stephen R. Comeau
IPC: C07K16/40
CPC classification number: C07K16/40 , C07K2317/34 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Disclosed herein are antibodies capable of binding to plasma kallikrein and inhibit its activity. Such antibodies interact with one or more critical residues in the catalytic domain of the plasma kallikrein. The antibodies may also contain specific heavy chain complementarity determining region 3 (CDRs) motifs and optionally specific residues at certain positions within both the heavy chain variable region and the light chain variable region.
-
公开(公告)号：US12097199B2
公开(公告)日：2024-09-24
申请号：US17258845
申请日：2019-07-08
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Sai Murali Krishna Pulukuri
IPC: A61K31/505 , A61P35/02 , C07K16/28
CPC classification number: A61K31/505 , A61P35/02 , C07K16/2887
Abstract: The present disclosure provides methods, pharmaceutical compositions, and kits for treating cancer or autoimmune disease in patients in need thereof. The methods comprise administering to a patient in need a small ubiquitin-like modifier (SUMO) activating enzyme (SAE) inhibitor, such as [(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxy-cyclopentyl]methyl sulfamate (Compound I-263a) or a pharmaceutically acceptable salt, in combination with one or more anti-CD20 antibodies. Also provided are medicaments for use in treating cancer or autoimmune disease.
-
公开(公告)号：US12097198B2
公开(公告)日：2024-09-24
申请号：US17866203
申请日：2022-07-15
Inventor： Vijaykumar Reddy Rajasekhar , Brendan Mark Johnson , David B. Maclean , Lynn Seely , Paul N. Mudd, Jr. , Hélène M. Faessel
IPC: A61K31/517 , A61K9/00 , A61K31/4164 , A61K31/4166 , A61K31/501 , A61K31/513 , A61P35/00
CPC classification number: A61K31/501 , A61K9/0053 , A61K31/4166 , A61K31/513 , A61P35/00
Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof; and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20240309016A1
公开(公告)日：2024-09-19
申请号：US18606857
申请日：2024-03-15
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Mitsunori KONO , Yusuke SASAKI , Yuya OGURO , Zenichi IKEDA , Osamu KUBO , Masaki SETO , Toru YAMASHITA , Makoto KAMATA , Kenjiro SATO , Matthew Thomas REYNOLDS , Kazuaki TAKAMI , Asato KINA , Takafumi YUKAWA , Minoru NAKAMURA , Taku KAMEI , Hiroyuki KAKEI , Fumie YAMAGUCHI , Tomohiro OHASHI , Keiko KAKEGAWA , Takuto KOJIMA , Florian PÜNNER , Masataka MURAKAMI , Takahiko TANIGUCHI , Tatsuki KOIKE , Yuichi KAJITA , Yuhei MIYANOHANA , Kohei TAKEUCHI , Yoshiteru ITO , Norihito TOKUNAGA , Yasushi HATTORI , Eiji KIMURA , Martin Alexander PAWLICZEK , Marilena PIRA , Shuhei IKEDA , Noriyuki TEZUKA , Yoshikazu WATANABE , Kevin CURRAN , Nicolle DOERING , Maria HOPKINS , Ben JOHNSON , Andre KIRYANOV , Jon LAM , Sean MURPHY , Natasha O'ROURKE , Holly REICHARD , Paul TANIS , Yunlong ZHANG
IPC: C07D498/14 , A61K31/407 , A61K31/437 , A61P25/26 , C07D498/04
CPC classification number: C07D498/14 , A61K31/407 , A61K31/437 , A61P25/26 , C07D498/04
Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):
wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.-
Patent Agency Ranking
公开(公告)号：US12091675B2
公开(公告)日：2024-09-17
申请号：US17296944
申请日：2019-07-15
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Hanspeter Rottensteiner , Werner Hoellriegl
IPC: C12N15/861 , A61K38/37 , A61K48/00 , C07K14/755
CPC classification number: C12N15/861 , A61K38/37 , A61K48/0083 , C07K14/755 , A01K2217/075 , A01K2227/105 , A01K2267/0381
Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A. In some embodiments, the present disclosure provides methods for dosing a hemophilia A patient with a polynucleotide, e.g., a codon-altered polynucleotide, encoding a Factor VIII polypeptide.
-
公开(公告)号：US12084515B2
公开(公告)日：2024-09-10
申请号：US17345033
申请日：2021-06-11
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Gregory P. Conley , Andrew Nixon , Daniel J. Sexton
CPC classification number: C07K16/40 , A61P27/02 , A61K9/0051 , A61K2039/505 , A61K2039/54 , C07K2317/30 , C07K2317/55 , C07K2317/76 , C07K2317/92
Abstract: Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.
-
公开(公告)号：US12084436B2
公开(公告)日：2024-09-10
申请号：US17426971
申请日：2020-01-29
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Masahiro Ito , Takeshi Yamamoto , Keiko Kakegawa , Hideyuki Sugiyama , Tohru Miyazaki , Yasuyoshi Arikawa , Tomohiro Okawa , Jinichi Yonemori , Osamu Kubo , Akinori Toita , Takuto Kojima , Fumiaki Kikuchi , Minoru Sasaki , Misaki Homma , Yasuhiro Imaeda , Hironobu Maezaki , Shiinobu Sasaki , Ayumu Sato , Hirotaka Kamitani , Yasutomi Asano , Hironori Kokubo , Masato Yoshikawa
IPC: C07D413/10 , C07D271/06 , C07D413/14 , C07D417/14
CPC classification number: C07D413/10 , C07D271/06 , C07D413/14 , C07D417/14
Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I):
wherein each symbol is as described in the description, or a salt thereof.-
公开(公告)号：US12077522B2
公开(公告)日：2024-09-03
申请号：US17256330
申请日：2019-06-27
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Tatsuhiko Fujimoto , Koichiro Fukuda , Hiromichi Sugimoto , Kentaro Rikimaru , Yoshihiro Banno , Takahiro Matsumoto , Norihito Tokunaga , Yoshihide Tomata , Yuji Ishichi , Shogo Marui , Tsuneo Oda , Tohru Miyazaki , Yasutaka Hoashi , Yasushi Hattori , Yuichi Kajita , Yuhei Miyanohana , Tatsuki Koike
IPC: C07D401/14 , C07D211/56 , C07D405/14
CPC classification number: C07D401/14 , C07D211/56 , C07D405/14
Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):
wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.-
公开(公告)号：US20240216426A1
公开(公告)日：2024-07-04
申请号：US18557559
申请日：2022-04-27
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Nandhu SOBHANA , Alisha BOTHUN , Gil BENEZER , Shruti BADKAR , Rabi MISHRA , Hui-Hsin CHANG , Wanwen LI , Mansi SONI , Lan CAO , Xi SHl , Jane YEH , Mengyao LUO , Manoj GUPTA , Akito NAKAMURA , Doanh MAI , Mei Rosa NG
IPC: A61K35/15 , A61K39/00 , C07K14/54 , C07K14/705
CPC classification number: A61K35/15 , A61K39/463 , C07K14/54 , C07K14/5443 , C07K14/70575 , C07K2319/03 , C07K2319/30 , C12N2501/2315 , C12N2501/2321 , C12N2506/45 , C12N2510/00
Abstract: The present disclosure provides recombinant antigen presenting cells and methods of use thereof in the culture and expansion of immune cells ex vivo. In some aspects, immune cells expanded through co-culture of the recombinant antigen presenting cells disclosed herein are administered to a subject to treat a disease or condition in the subject, e.g., to treat a cancer.
-
-
-
-
-
-
-
-
-
Search Results
2080
records
(took 0.034 seconds)
